Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 37
Filtrar
1.
Zhonghua Yu Fang Yi Xue Za Zhi ; 56(9): 1203-1210, 2022 Sep 06.
Artículo en Chino | MEDLINE | ID: mdl-36207881

RESUMEN

Disorders of sex development (DSD) is a class of diseases characterized by discordant phenotypes of sex chromosome karyotypes, gonads and external genitalia. The etiology is complex and the clinical manifestations are varied. Understanding the clinical characteristics of patients with various types of DSD help make accurate etiological diagnosis and prepare individualized treatment plans according to the etiology (including sex assignment, endocrine hormone replacement, surgery and fertility protection, etc.). Due to the increased risk of DSD in the second pregnancy of the parents of DSD patients, early preventive measures such as pre-pregnancy genetic counseling and prenatal diagnosis during pregnancy can effectively avoid or reduce the risk of DSD in their siblings.


Asunto(s)
Trastornos del Desarrollo Sexual , Trastornos del Desarrollo Sexual/diagnóstico , Trastornos del Desarrollo Sexual/genética , Trastornos del Desarrollo Sexual/prevención & control , Femenino , Hormonas , Humanos , Embarazo , Hermanos
2.
Endocrinol Metab Clin North Am ; 45(2): 267-81, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-27241964

RESUMEN

Congenital adrenal hyperplasia (CAH) owing to 21-hydroxylase deficiency is a monogenic disorder of adrenal steroidogenesis. To prevent genital ambiguity, in girls, prenatal dexamethasone treatment is administered early in the first trimester. Prenatal genetic diagnosis of CAH and fetal sex determination identify affected female fetuses at risk for genital virilization. Advancements in prenatal diagnosis are owing to improved understanding of the genetic basis of CAH and improved technology. Cloning of the CYP21A2 gene ushered in molecular genetic analysis as the current standard of care. Noninvasive prenatal diagnosis allows for targeted treatment and avoids unnecessary treatment of males and unaffected females.


Asunto(s)
Hiperplasia Suprarrenal Congénita/diagnóstico , Diagnóstico Prenatal , Dexametasona/uso terapéutico , Trastornos del Desarrollo Sexual/prevención & control , Femenino , Humanos , Masculino , Embarazo
3.
Eur. j. anat ; 20(2): 113-120, abr. 2016. ilus
Artículo en Inglés | IBECS | ID: ibc-152867

RESUMEN

Prenatal and one-two month postnatal testosterone influences human neural and behavioural development, since the prenatal and one-two month postnatal hormone environment clearly contributes to the development of sex-related variation in human behaviour, and plays a role in the development of the sexual brain and individual differences in behaviour within each sex, as well as differences between the sexes. Olfactory system development, brain sexual maturation and sexual behaviour in man and animals are closely related. Kallmann syndrome (KS) is a genetic disorder which combines hypogonadotropic hypogonadism and anosmia. Hypogonadism is characterized by the absence or reduced levels of gonadotropinreleasing hormone, and anosmia is due to aplasia of the olfactory bulb. The overlap between the formation of the olfactory system and the migration of neurons that synthesize the gonadotropinreleasing hormone (GnRH) is common knowledge. GnRH neurons migrate from the medial portion of the nasal epithelium through the olfactory nerves and the main olfactory bulb to the anterior hypothalamus. Furthermore, the clinical manifestations of KS are: anosmia, the absence of puberty, and modifications in sexual behaviour. The structures responsible for the maturation of the main and accessory olfactory systems, the sexual differentiation of the brain and its relationship with clinical manifestations and sexual behaviour in Kallmann syndrome are analyzed in this review. The importance of the treatment of KS at early ages is suggested in order to improve brain sexual development and its clinical and sexual behaviour manifestations


No disponible


Asunto(s)
Humanos , Síndrome de Kallmann/fisiopatología , Desarrollo Sexual/fisiología , Trastornos del Desarrollo Sexual/prevención & control , Conducta Sexual , Diferenciación Sexual/fisiología , Bulbo Olfatorio/embriología , Hipotálamo Anterior/embriología , Amígdala del Cerebelo/embriología
6.
J Pediatr Endocrinol Metab ; 26(9-10): 949-53, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23729539

RESUMEN

We report an 18-year-old Japanese male with a lack of secondary sex characterization and growth failure caused by a rare association between Rathke's cyst and hypophysitis. He was referred to us because of delayed secondary sex characterization. Endocrinological examination showed panhypopituitarism, and the replacement of hydrocortisone, levothyroxine, and desmopressin acetate (DDAVP) was initiated. Brain magnetic resonance imaging (MRI) showed a suprasellar region and a swollen pituitary stalk. The mass was partially resected using the transsphenoidal approach. The pathological diagnosis was hypophysitis and Rathke's cyst. Follow-up MRI performed 1 year after surgery showed that the size of sellar region had not changed. After surgery, in addition to pre-operative hormonal replacement, growth hormone and testosterone were initiated. Two years later, the size of sellar region remains unchanged. In conclusion, while an association between Rathke's cyst and hypophysitis is rare, we suggest that this condition should be included in differential diagnosis of the sellar region, even in adolescents.


Asunto(s)
Quistes del Sistema Nervioso Central/complicaciones , Trastornos del Desarrollo Sexual/etiología , Trastornos del Crecimiento/etiología , Hipopituitarismo/complicaciones , Hipófisis/inmunología , Neoplasias Hipofisarias/complicaciones , Adolescente , Desarrollo del Adolescente/efectos de los fármacos , Quistes del Sistema Nervioso Central/fisiopatología , Quistes del Sistema Nervioso Central/cirugía , Trastornos del Desarrollo Sexual/prevención & control , Trastornos del Crecimiento/prevención & control , Terapia de Reemplazo de Hormonas , Hormona de Crecimiento Humana/uso terapéutico , Humanos , Hipopituitarismo/tratamiento farmacológico , Hipopituitarismo/inmunología , Hipopituitarismo/fisiopatología , Masculino , Tamaño de los Órganos/efectos de los fármacos , Hipófisis/patología , Hipófisis/fisiopatología , Hipófisis/cirugía , Neoplasias Hipofisarias/fisiopatología , Neoplasias Hipofisarias/cirugía , Testosterona/uso terapéutico , Resultado del Tratamiento
10.
J Nutr Sci Vitaminol (Tokyo) ; 57(5): 333-9, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22293210

RESUMEN

The purpose of this study was to clarify the effects of nutrients on the gonadal development of male rats kept under constant darkness as a model of disturbed daily rhythm. In the present study we examined fat-soluble vitamins and their interactions in this test population. Four fat-soluble vitamins (vitamin A (V.A), vitamin D (V.D), vitamin E (V.E) and vitamin K (V.K)) were selected as experimental factors, and the dietary content of these vitamins was normal (AIN-93G) or three times the normal content. Lighting conditions (constant darkness or normal lighting) were also added as a factor. Four-week-old rats (Fischer 344 strain) were kept under constant darkness or normal lighting (12-h light/dark cycle) for 4 wk. The lighting condition and V.E, and the interactions between the lighting condition and V.E and between V.A and V.D were observed to affect the testes and epididymides weights. There was an influence of the lighting condition only on the seminal vesicles and prostate weights and the serum testosterone concentration. Among the constant darkness groups (D-groups), the highest value for testes weight was observed under the normal-V.A, normal-V.D and high-V.E diet. The interaction between lighting condition and V.E showed the testes weight increased slightly in response to changing to a high-V.E diet from a normal-V.E diet under normal lighting (N-group) but was greatly increased in response to this change in the D-group. It became clear that the amount of dietary V.E necessary for the gonadal development of rats increases when rats are kept under constant darkness.


Asunto(s)
Trastornos Cronobiológicos/fisiopatología , Trastornos del Desarrollo Sexual/prevención & control , Genitales Masculinos/patología , Vitamina A/uso terapéutico , Vitamina D/uso terapéutico , Vitamina E/uso terapéutico , Animales , Suplementos Dietéticos , Trastornos del Desarrollo Sexual/etiología , Trastornos del Desarrollo Sexual/metabolismo , Trastornos del Desarrollo Sexual/patología , Ingestión de Energía , Epidídimo/patología , Masculino , Tamaño de los Órganos , Fotoperiodo , Próstata/patología , Ratas , Ratas Endogámicas F344 , Vesículas Seminales/patología , Testículo/crecimiento & desarrollo , Testosterona/sangre , Vitamina K/uso terapéutico
12.
Am J Bioeth ; 10(9): 35-45, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20818559

RESUMEN

On February 3, 2010, a "Letter of Concern from Bioethicists," organized by fetaldex.org, was sent to report suspected violations of the ethics of human subjects research in the off-label use of dexamethasone during pregnancy by Dr. Maria New. Copies of this letter were submitted to the FDA Office of Pediatric Therapeutics, the Department of Health and Human Services (DHHS) Office for Human Research Protections, and three universities where Dr. New has held or holds appointments. We provide a critical appraisal of the Letter of Concern and show that it makes false claims, misrepresents scientific publications and websites, fails to meet standards of evidence-based reasoning, makes undocumented claims, treats as settled matters what are, instead, ongoing controversies, offers "mere opinion" as a substitute for argument, and makes contradictory claims. The Letter of Concern is a case study in unethical transgressive bioethics. We call on fetaldex.org to withdraw the letter and for co-signatories to withdraw their approval of it.


Asunto(s)
Hiperplasia Suprarrenal Congénita/diagnóstico , Hiperplasia Suprarrenal Congénita/tratamiento farmacológico , Correspondencia como Asunto , Dexametasona/administración & dosificación , Trastornos del Desarrollo Sexual/prevención & control , Eticistas/normas , Enfermedades Fetales/tratamiento farmacológico , Genitales Femeninos/anomalías , Uso Fuera de lo Indicado , Diagnóstico Prenatal , Experimentación Humana Terapéutica/ética , Hiperplasia Suprarrenal Congénita/complicaciones , Hiperplasia Suprarrenal Congénita/enzimología , Ensayos Clínicos como Asunto , Trastornos del Desarrollo Sexual/etiología , Esquema de Medicación , Comités de Ética en Investigación , Femenino , Enfermedades Fetales/diagnóstico , Enfermedades Fetales/enzimología , Genitales Femeninos/cirugía , Glucocorticoides/administración & dosificación , Humanos , Consentimiento Informado/ética , Masculino , Uso Fuera de lo Indicado/ética , Embarazo , Procedimientos de Cirugía Plástica , Derivación y Consulta , Esteroide 21-Hidroxilasa/metabolismo , Estados Unidos , United States Food and Drug Administration , Virilismo/prevención & control
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA